WO2000063369A3 - Gene therapy - Google Patents
Gene therapy Download PDFInfo
- Publication number
- WO2000063369A3 WO2000063369A3 PCT/EP2000/003532 EP0003532W WO0063369A3 WO 2000063369 A3 WO2000063369 A3 WO 2000063369A3 EP 0003532 W EP0003532 W EP 0003532W WO 0063369 A3 WO0063369 A3 WO 0063369A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- gene therapy
- fasr
- fgfr
- progenitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45527/00A AU4552700A (en) | 1999-04-19 | 2000-04-18 | Gene therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29417699A | 1999-04-19 | 1999-04-19 | |
US09/294,176 | 1999-04-19 | ||
US30769099A | 1999-05-10 | 1999-05-10 | |
US09/307,690 | 1999-05-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000063369A2 WO2000063369A2 (en) | 2000-10-26 |
WO2000063369A3 true WO2000063369A3 (en) | 2001-04-26 |
Family
ID=26968381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/003532 WO2000063369A2 (en) | 1999-04-19 | 2000-04-18 | Gene therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4552700A (en) |
WO (1) | WO2000063369A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
JP2023509742A (en) * | 2020-01-06 | 2023-03-09 | メモリアル スローン ケタリング キャンサー センター | Novel dominant-negative FAS polypeptides, cells containing them, and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0510691A1 (en) * | 1991-04-26 | 1992-10-28 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
US5229501A (en) * | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
WO1996020206A1 (en) * | 1994-12-23 | 1996-07-04 | Uab Research Foundation | Secreted human fas antigen |
WO1999055861A2 (en) * | 1998-04-28 | 1999-11-04 | Eisai Co., Ltd. | Fibroblast growth factor mutein compositions and methods of use therefor |
WO2000039311A1 (en) * | 1998-12-31 | 2000-07-06 | Advanced Research And Technology Institute | Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
WO2000046380A2 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
-
2000
- 2000-04-18 WO PCT/EP2000/003532 patent/WO2000063369A2/en active Application Filing
- 2000-04-18 AU AU45527/00A patent/AU4552700A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229501A (en) * | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
EP0510691A1 (en) * | 1991-04-26 | 1992-10-28 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
WO1996020206A1 (en) * | 1994-12-23 | 1996-07-04 | Uab Research Foundation | Secreted human fas antigen |
WO1999055861A2 (en) * | 1998-04-28 | 1999-11-04 | Eisai Co., Ltd. | Fibroblast growth factor mutein compositions and methods of use therefor |
WO2000039311A1 (en) * | 1998-12-31 | 2000-07-06 | Advanced Research And Technology Institute | Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
WO2000046380A2 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
Non-Patent Citations (3)
Title |
---|
BELLOSTA P ET AL: "CLEAVAGE OF K-FGF PRODUCES A TRUNCATED MOLECULE WITH INCREASED BIOLOGICAL ACTIVITY AND RECEPTOR BINDING AFFINITY", JOURNAL OF CELL BIOLOGY,ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US,US, vol. 121, no. 3, May 1993 (1993-05-01), pages 705 - 713, XP000942993, ISSN: 0021-9525 * |
LUO W ET AL: "Gene transfer of soluble FGF receptor 1 (sFGFR1) reduces accelerated graft arteriosclerosis (AGA).", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. PROGRAM AND ABSTR. ISSUE, September 1999 (1999-09-01), 32nd Annual Meeting of the American Society of Nephrology;Miami Beach, Florida, USA; November 1-8, 1999, pages 447A, XP000972013, ISSN: 1046-6673 * |
MAHIOU JEROME ET AL: "Soluble FasR ligand-binding domain: High-yield production of active fusion and non-fusion recombinant proteins using the baculovirus/insect cell system.", BIOCHEMICAL JOURNAL, vol. 330, no. 2, 1 March 1998 (1998-03-01), pages 1051 - 1058, XP002154103, ISSN: 0264-6021 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000063369A2 (en) | 2000-10-26 |
AU4552700A (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2296769A1 (en) | Modified dorsal tissue affecting factor and compositions | |
AU3455499A (en) | Delivery catheter system for heart chamber | |
WO2000006133A3 (en) | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | |
AU2989300A (en) | Controlling protein levels in eucaryotic organisms | |
WO2003014307A3 (en) | Antisense modulation of apolipoprotein(a) expression | |
WO2001080896A3 (en) | Flavopiridol drug combinations and methods with reduced side effects | |
AU4485600A (en) | Gaming system with central control | |
AU3520900A (en) | Implantable drug delivery system | |
WO2002061076A1 (en) | Adiponectin-associated protein | |
AU6114700A (en) | Novel system for the sequential, directional cloning of multiple dna sequences | |
WO1994005791A3 (en) | Dorsal tissue affecting factor and compositions | |
WO2003023004A3 (en) | Antisense modulation of fibroblast growth factor receptor 3 expression | |
WO1997022695A3 (en) | Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer | |
WO2003048205A3 (en) | Novel proteins with il-6 inhibiting activity | |
AU6181000A (en) | Novel genes encoding protein kinase/protein phosphatase | |
AU4905700A (en) | Neural transplantation delivery system | |
EP1224202A4 (en) | Antisense modulation of integrin-linked kinase expression | |
EP1218398A4 (en) | Antisense modulation of pi3 kinase p110 beta expression | |
WO2001029175A3 (en) | Antisense modulation of fra-1 expression | |
AU5305000A (en) | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses | |
AU6180900A (en) | Novel genes encoding protein kinase/protein phosphatase | |
EP1250347A4 (en) | Antisense modulation of akt-3 expression | |
WO2001002020A3 (en) | Compositions and methods for targeted enzymatic release of cell regulatory compounds | |
WO2000063369A3 (en) | Gene therapy | |
EP1165145A4 (en) | Antisense modulation of mdmx expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |